lobbying_filings_raw: 4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | amount_reported | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14 | Q3 | 57954 | TAKEDA PHARMACEUTICALS AMERICA, INC. | 160416 | TAKEDA PHARMACEUTICALS AMERICA INC | 2012 | third_quarter | 2012-10-16T14:32:54.040000-04:00 | 280000.0 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14/", "filing_uuid": "4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14", "filing_type": "Q3", "filing_type_display": "3rd Quarter - Report", "filing_year": 2012, "filing_period": "third_quarter", "filing_period_display": "3rd Quarter (July 1 - Sep 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14/print/", "filing_document_content_type": "text/html", "income": null, "expenses": "280000.00", "expenses_method": "a", "expenses_method_display": "Method A - Reporting amounts using LDA definitions only", "posted_by_name": "Laura Cline, Senior Director, Federal Governmental Affairs", "dt_posted": "2012-10-16T14:32:54.040000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "750 9th Street, NW", "registrant_address_2": "Suite 575", "registrant_different_address": false, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20001", "registrant": {"id": 57954, "url": "https://lda.senate.gov/api/v1/registrants/57954/", "house_registrant_id": 35264, "name": "TAKEDA PHARMACEUTICALS AMERICA, INC.", "description": "Pharmaceutical Company", "address_1": "670 Maine Ave SW", "address_2": "Suite 210", "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20024", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "ANDREW KAPLAN", "contact_telephone": "+1 202-649-4004", "dt_updated": "2026-01-28T13:02:39.074403-05:00"}, "client": {"id": 160416, "url": "https://lda.senate.gov/api/v1/clients/160416/", "client_id": 12, "name": "TAKEDA PHARMACEUTICALS AMERICA INC", "general_description": null, "client_government_entity": false, "client_self_select": true, "state": "DC", "state_display": "District of Columbia", "country": "US", "country_display": "United States of America", "ppb_state": "DC", "ppb_state_display": "District of Columbia", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2009-11-01"}, "lobbying_activities": [{"general_issue_code": "TRD", "general_issue_code_display": "Trade (domestic/foreign)", "description": "Counterfiet drugs, serialization and development of tracibility model", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 46458, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "DEBORAH", "nickname": null, "middle_name": "LYNN", "last_name": "WALTER", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "ACA implications of SCOTUS ruling", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 46456, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "LAURA", "nickname": null, "middle_name": "ELIZABETH", "last_name": "CLINE", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "PDUFA", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 46456, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "LAURA", "nickname": null, "middle_name": "ELIZABETH", "last_name": "CLINE", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "Medicare reform; Product portfolio; depression drugs, CNS", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 46458, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "DEBORAH", "nickname": null, "middle_name": "LYNN", "last_name": "WALTER", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 46456, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "LAURA", "nickname": null, "middle_name": "ELIZABETH", "last_name": "CLINE", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "BUD", "general_issue_code_display": "Budget/Appropriations", "description": "Implications of deficit reduction", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 46456, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "LAURA", "nickname": null, "middle_name": "ELIZABETH", "last_name": "CLINE", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | DC | US | 35264 | DC | DC | US | US | 0 | 0 | 2356683 | normalized_name_dc_fallback | 0.8 |